국가: 네덜란드
언어: 네덜란드어
출처: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
TAMSULOSINEHYDROCHLORIDE 0,4 mg/stuk SAMENSTELLING overeenkomend met ; TAMSULOSINE 0,37 mg/stuk
Zentiva a.s. U. Kabelovny 130 10237 PRAGUE (TSJECHIË)
G04CA02
TAMSULOSINEHYDROCHLORIDE 0,4 mg/stuk SAMENSTELLING overeenkomend met ; TAMSULOSINE 0,37 mg/stuk
Tablet met verlengde afgifte
CARBOMEER 71G-NF ; CELLULOSE, MICROKRISTALLIJN (E 460(i)) ; HYPROMELLOSE, type 2208 (Release controlling polymer), K100M (E 464) ; IJZEROXIDE ROOD (E 172) ; MAGNESIUMSTEARAAT (E 470b) ; SILICIUMDIOXIDE (E 551), CARBOMEER 71G-NF ; CELLULOSE, MICROKRISTALLIJN (E 460) ; HYPROMELLOSE, type 2208 (Release controlling polymer), K15M, K100M (E 464) ; IJZEROXIDE ROOD (E 172) ; MAGNESIUMSTEARAAT (E 470b) ; SILICIUMDIOXIDE (E 551), CARBOMEER 71G-NF ; CELLULOSE, MICROKRISTALLIJN (E 460) ; HYPROMELLOSE, type 2208 (Release controlling polymer), K100M (E 464) ; IJZEROXIDE ROOD (E 172) ; MAGNESIUMSTEARAAT (E 470b) ; SILICIUMDIOXIDE (E 551),
Oraal gebruik
Tamsulosin
Hulpstoffen: CARBOMEER 71G-NF; CELLULOSE, MICROKRISTALLIJN (E 460); HYPROMELLOSE, type 2208 (Release controlling polymer), K100M (E 464); IJZEROXIDE ROOD (E 172); MAGNESIUMSTEARAAT (E 470b); SILICIUMDIOXIDE (E 551);
1900-01-01
Common Technical Document Tamsulosin hydrochloride 0.4 mg Prolonged release tablets Document number (version): M13.1-03.TSL.hcl.mrt.002.03.core Page 1 of 6 1.3.1 PACKAGE LEAFLET PACKAGE LEAFLET: INFORMATION FOR THE USER TAMSULOSINE HCL ZENTIVA 0,4 MG, TABLETTEN MET VERLENGDE AFGIFTE tamsulosine hydrochloride READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. IN THIS LEAFLET: 1. Whatis and what it is used for 2. What you need to know before you take 전체 문서 읽기3. How to take 4. Possible side effects 5. How to store 6. Contents of the pack and other information 1 WHAT IS AND WHAT IT IS USED FOR Tamsulosin relaxes the muscles in the prostate and urinary tract. By relaxing the muscle tamsulosin enables a more easily pass of urine and helps urination. In addition, it diminishes sensations of urge. Tamsulosin is prescribed in men to alleviate urinary symptoms caused by an enlarged prostrate (benign prostatic hyperplasia). These symptoms may include difficulty urinating (poor stream), dribbling, urgency and having to urinate frequently at night as well as during the day. 2 WHAT YOU NEED TO KNOW BEFORE YOU TAKE DO NOT TAKE IF YOU: are ALLERGIC TO TAMSULOSIN OR ANY OF THE OTHER INGREDIENTS of this medicine (listed in section 6). Hypersensitivity may present a sudden local swelling of the soft tissues of
Common Technical Document Tamsulosin hydrochloride 0.4 mg Prolonged release tablets Document number (version): M13.1-01.TSL.hcl.mrt.002.05.core Page 1 of 11 SUMMARY OF PRODUCT CHARACTERISTICS - CORE 1. NAME OF THE MEDICINAL PRODUCT Tamsulosine HCI Zentiva 0,4 mg, tabletten met verlengde afgifte 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each prolonged-release tablet contains 0.400 mg 400 microgram tamsulosin hydrochloride, equivalent to 0.367 mg 367 microgram tamsulosin. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Prolonged-release tablet. White, un-scored, round tablets with a diameter of 9 mm, debossed on one side with "T9SL” and “0.4” on the other side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology One tablet daily. Tamsulosin can be taken independently of food. Common Technical Document Tamsulosin hydrochloride 0.4 mg Prolonged release tablets Document number (version): M13.1-01.TSL.hcl.mrt.002.05.core Page 2 of 11 _Renal impairment _ No dose adjustment is warranted in renal impairment. _ _ _Hepatic impairment_ No dose adjustment is warranted in patients with mild to moderate hepatic insufficiency (see also 4.3, Contraindications). _Paediatric population _ There is no relevant indication for use of tamsulosin in children._ _ The safety and efficacy of tamsulosin in children and adolescents have not been established. Currently available data are described in section 5.1. Method of administration Oral use. The tablet must be swallowed whole and not be crunched or chewed as this interferes with the prolonged release of the active substance. 4.3 CONTRAINDICATIONS Hypersensitivity to the active substance, including drug-induced angioedema, or to any of the excipients listed in section 6.1. A history of orthostatic hypotension. Severe hepatic insufficiency. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE As with other α 1 -adre 전체 문서 읽기